Anastrozole Show Benefits Over Tamoxifen

Anastrozole Show Benefits Over Tamoxifen: “Five-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial continue to suggest that anastrozole is superior to tamoxifen in the treatment of postmenopausal women with early-stage breast cancer. Principal investigator Anthony Howell, MD, professor, department of medical oncology, Christie Hospital NHS Trust, and director, research and development, … Read moreAnastrozole Show Benefits Over Tamoxifen

Aromasin & Tamoxifen During Post Cycle Therapy

Aromasin (Exemestane) is one of those weird compounds that nobody really knows what to do with. What we generally hear about it makes it very uninteresting…It’s a third generation Aromatase Inhibitor (AI) just like Arimidex (Anastrozole) and Femera (Letrozole). Both of those two drugs are very efficient at stopping the conversion of androgens into estrogen, and since we have them, why bother with Aromasin? It’s a little harder to get than the other two commonly used aromatase inhibitors, because it’s not in high demand, and there’s never been a readily apparent advantage to using it. And I mean…lets face it: It’s awkward-sounding. Aromasin doesn’t have much of a ring to it, and exemestane is even worse. Arimidex (Anastrozole) has a bunch of cool abbreviations (“A-dex” or just ‘dex) and even Letrozole is just “Letro” to most people. Where’s the cool nickname forAromasin/exemestane? A-Sin? E-Stane? It just doesn’t work. It’s the black sheep of AIs. And why do we even need it when we have Letrozole, which is by far the most efficient AI for stopping aromatization (the process by which your body converts testosterone into estrogen)? Letro can reduce estrogen levels by 98% or greater; clinically a dose as low as 100mcgs has been shown to provide maximum aromatase inhibition!

Read moreAromasin & Tamoxifen During Post Cycle Therapy